The Experts below are selected from a list of 468 Experts worldwide ranked by ideXlab platform
Melvyn R Danzig - One of the best experts on this subject based on the ideXlab platform.
-
effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis
Annals of Allergy Asthma & Immunology, 2002Co-Authors: Anjuli Nayak, Guy A Settipane, Andrew Pedinoff, Lauren B Charous, Eli O Meltzer, William W Busse, James S Zinreich, Richard R Lorber, Ger Rikken, Melvyn R DanzigAbstract:Background Mometasone furoate nasal spray (MFNS) 400 μg, twice daily, as adjunctive treatment with oral antibiotic significantly improved symptoms of recurrent rhinosinusitis. Objective To evaluate the effectiveness and safety of MFNS 200 μg, twice daily, and 400 μg, twice daily, compared with placebo as adjunctive treatment with oral antibiotic for acute rhinosinusitis. Methods In this multicenter, double-blind, placebo-controlled study, 967 outpatients with computed tomographic scan-confirmed moderate to severe rhinosinusitis received amoxicillin/Clavulanate Potassium (Augmentin, GlaxoSmithKline, Research Triangle Park, NC) 875 mg, twice daily, for 21 days with adjunctive twice daily MFNS 200 μg, MFNS 400 μg, or placebo nasal spray. Patients recorded scores of six rhinosinusitis symptoms and any adverse events twice daily. Pre- and postcosyntropin–stimulation plasma cortisol levels were measured in a subset of patients at selected study sites. Results Treatment with MFNS 200 μg or 400 μg, twice daily, produced significantly greater improvements in total symptoms score (primary efficacy variable) day 1 to day 15 average (50% and 51%, respectively) than placebo (44%, P ≤0.017). Both doses of MFNS produced significant total symptoms score improvement over placebo by day 4, and maintained efficacy over the entire 21-day study. Relief of individual symptoms showed a similar pattern. Both doses of MFNS were well tolerated, and adverse events were similar to that of placebo. Cosyntropin stimulation showed no evidence of hypothalamic-pituitary-adrenal axis suppression. Conclusions As adjunctive therapy to oral antibiotic treatment, MFNS at doses of 200 μg or 400 μg, twice daily, was well tolerated and significantly more effective in reducing the symptoms of rhinosinusitis than antibiotic therapy alone.
-
added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Eli O Meltzer, Lauren B Charous, William W Busse, James S Zinreich, Richard R Lorber, Melvyn R DanzigAbstract:Abstract Background: Intranasal glucocorticoids are effective in the treatment of allergic rhinitis. Their effectiveness as an anti-inflammatory adjunct in the treatment of acute recurrent sinusitis has not been adequately established in a controlled clinical study. Objective: The purpose of this study was to test the hypothesis that intranasal corticosteroid treatment produces additional relief in the treatment of acute sinusitis with oral antibiotics. Methods: Patients who were 12 years old and older with a history of recurrent sinusitis were treated while experiencing a new episode of acute sinusitis, which was diagnosed by symptoms and confirmed by computed tomography scan of the paranasal sinuses. Patients were treated for 21 days with amoxicillin Clavulanate Potassium and randomized to receive concurrent mometasone furoate nasal spray (MFNS; Nasonex [400 μg, twice daily]; n=200 patients) or placebo spray (twice daily; n=207 patients). Symptom scores for headache, facial pain, congestion, purulent rhinorrhea, postnasal drip, and cough were recorded at baseline and throughout treatment. Results: Baseline symptom scores showed a moderate level of symptom severity comparable in both groups. Patient-recorded twice daily symptom scores showed that adjunctive treatment with MFNS caused a significantly greater decrease in total symptom score (primary efficacy variable) and in individual scores of inflammatory symptoms associated with the obstruction process (headache, congestion, and facial pain) compared with placebo. Symptoms associated with the secretory processes were improved to a lesser degree. Therapy-related local adverse events were not significantly different between groups. Conclusion: The addition of intranasal corticosteroid, MFNS 400 μg twice daily, to antibiotics significantly reduces symptoms of acute sinusitis compared with antibiotic treatment alone. (J Allergy Clin Immunol 2000;106:630-7.)
Edgar Mohs - One of the best experts on this subject based on the ideXlab platform.
-
comparative trial of 3 day azithromycin versus 10 day amoxycillin Clavulanate Potassium in the treatment of children with acute otitis media with effusion
International Journal of Antimicrobial Agents, 1996Co-Authors: Adriano Arguedas, Cecilia Loaiza, Marcos Herrera, Edgar MohsAbstract:A randomized, open clinical trial was performed to compare azithromycin and amoxycillin/Clavulanate Potassium in children with acute otitis media with effusion. Patients were allocated to therapy with azithromycin (10 mg/kg once daily for 3 days) or amoxycillin/Clavulanate Potassium (40 mg/kg/day divided into three equal doses for 10 days). Clinical examination and tympanometric evaluation were performed at baseline, and at day 3 to 5, day 10 to 14, day 28 to 30 and day 55 to 60 after the initiation of therapy. Tympanocentesis fluid cultures were collected at enrolment, and urine and blood samples were obtained at baseline and at day 10 to 11. Of 100 patients enrolled, 92 were considered evaluable. Middle ear cultures were positive in 53.2% of the patients; the most common pathogens were Streptococcus pneumoniae (33%) and Haemophilus influenzae (33%). The response was satisfactory in 47 (100%) patients treated with azithromycin and 42 (95.4%) patients receiving A/C. Rates of persistence of middle ear effusion were comparable. Nausea and loose stools were more common in children treated with amoxycillin/Clavulanate Potassium (P < or = 0.02). Based on the comparable efficacy noted in this study, the lower incidence of side-effects and the convenience of a shorter duration of treatment, azithromycin represents an attractive therapeutic alternative to amoxycillin/Clavulanate Potassium and should be further evaluated in larger-scale clinical trials including patients with penicillin-resistant organisms.
Eli O Meltzer - One of the best experts on this subject based on the ideXlab platform.
-
effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis
Annals of Allergy Asthma & Immunology, 2002Co-Authors: Anjuli Nayak, Guy A Settipane, Andrew Pedinoff, Lauren B Charous, Eli O Meltzer, William W Busse, James S Zinreich, Richard R Lorber, Ger Rikken, Melvyn R DanzigAbstract:Background Mometasone furoate nasal spray (MFNS) 400 μg, twice daily, as adjunctive treatment with oral antibiotic significantly improved symptoms of recurrent rhinosinusitis. Objective To evaluate the effectiveness and safety of MFNS 200 μg, twice daily, and 400 μg, twice daily, compared with placebo as adjunctive treatment with oral antibiotic for acute rhinosinusitis. Methods In this multicenter, double-blind, placebo-controlled study, 967 outpatients with computed tomographic scan-confirmed moderate to severe rhinosinusitis received amoxicillin/Clavulanate Potassium (Augmentin, GlaxoSmithKline, Research Triangle Park, NC) 875 mg, twice daily, for 21 days with adjunctive twice daily MFNS 200 μg, MFNS 400 μg, or placebo nasal spray. Patients recorded scores of six rhinosinusitis symptoms and any adverse events twice daily. Pre- and postcosyntropin–stimulation plasma cortisol levels were measured in a subset of patients at selected study sites. Results Treatment with MFNS 200 μg or 400 μg, twice daily, produced significantly greater improvements in total symptoms score (primary efficacy variable) day 1 to day 15 average (50% and 51%, respectively) than placebo (44%, P ≤0.017). Both doses of MFNS produced significant total symptoms score improvement over placebo by day 4, and maintained efficacy over the entire 21-day study. Relief of individual symptoms showed a similar pattern. Both doses of MFNS were well tolerated, and adverse events were similar to that of placebo. Cosyntropin stimulation showed no evidence of hypothalamic-pituitary-adrenal axis suppression. Conclusions As adjunctive therapy to oral antibiotic treatment, MFNS at doses of 200 μg or 400 μg, twice daily, was well tolerated and significantly more effective in reducing the symptoms of rhinosinusitis than antibiotic therapy alone.
-
added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Eli O Meltzer, Lauren B Charous, William W Busse, James S Zinreich, Richard R Lorber, Melvyn R DanzigAbstract:Abstract Background: Intranasal glucocorticoids are effective in the treatment of allergic rhinitis. Their effectiveness as an anti-inflammatory adjunct in the treatment of acute recurrent sinusitis has not been adequately established in a controlled clinical study. Objective: The purpose of this study was to test the hypothesis that intranasal corticosteroid treatment produces additional relief in the treatment of acute sinusitis with oral antibiotics. Methods: Patients who were 12 years old and older with a history of recurrent sinusitis were treated while experiencing a new episode of acute sinusitis, which was diagnosed by symptoms and confirmed by computed tomography scan of the paranasal sinuses. Patients were treated for 21 days with amoxicillin Clavulanate Potassium and randomized to receive concurrent mometasone furoate nasal spray (MFNS; Nasonex [400 μg, twice daily]; n=200 patients) or placebo spray (twice daily; n=207 patients). Symptom scores for headache, facial pain, congestion, purulent rhinorrhea, postnasal drip, and cough were recorded at baseline and throughout treatment. Results: Baseline symptom scores showed a moderate level of symptom severity comparable in both groups. Patient-recorded twice daily symptom scores showed that adjunctive treatment with MFNS caused a significantly greater decrease in total symptom score (primary efficacy variable) and in individual scores of inflammatory symptoms associated with the obstruction process (headache, congestion, and facial pain) compared with placebo. Symptoms associated with the secretory processes were improved to a lesser degree. Therapy-related local adverse events were not significantly different between groups. Conclusion: The addition of intranasal corticosteroid, MFNS 400 μg twice daily, to antibiotics significantly reduces symptoms of acute sinusitis compared with antibiotic treatment alone. (J Allergy Clin Immunol 2000;106:630-7.)
Adriano Arguedas - One of the best experts on this subject based on the ideXlab platform.
-
comparative trial of 3 day azithromycin versus 10 day amoxycillin Clavulanate Potassium in the treatment of children with acute otitis media with effusion
International Journal of Antimicrobial Agents, 1996Co-Authors: Adriano Arguedas, Cecilia Loaiza, Marcos Herrera, Edgar MohsAbstract:A randomized, open clinical trial was performed to compare azithromycin and amoxycillin/Clavulanate Potassium in children with acute otitis media with effusion. Patients were allocated to therapy with azithromycin (10 mg/kg once daily for 3 days) or amoxycillin/Clavulanate Potassium (40 mg/kg/day divided into three equal doses for 10 days). Clinical examination and tympanometric evaluation were performed at baseline, and at day 3 to 5, day 10 to 14, day 28 to 30 and day 55 to 60 after the initiation of therapy. Tympanocentesis fluid cultures were collected at enrolment, and urine and blood samples were obtained at baseline and at day 10 to 11. Of 100 patients enrolled, 92 were considered evaluable. Middle ear cultures were positive in 53.2% of the patients; the most common pathogens were Streptococcus pneumoniae (33%) and Haemophilus influenzae (33%). The response was satisfactory in 47 (100%) patients treated with azithromycin and 42 (95.4%) patients receiving A/C. Rates of persistence of middle ear effusion were comparable. Nausea and loose stools were more common in children treated with amoxycillin/Clavulanate Potassium (P < or = 0.02). Based on the comparable efficacy noted in this study, the lower incidence of side-effects and the convenience of a shorter duration of treatment, azithromycin represents an attractive therapeutic alternative to amoxycillin/Clavulanate Potassium and should be further evaluated in larger-scale clinical trials including patients with penicillin-resistant organisms.
-
comparative trial of cefprozil vs amoxicillin Clavulanate Potassium in the treatment of children with acute otitis media with effusion
Pediatric Infectious Disease Journal, 1991Co-Authors: Adriano Arguedas, Harris R Stutman, Margaret Zaleska, Jeffrey L Blumer, Coralie S HainsAbstract:: A total of 137 children with acute otitis media with effusion were randomly allocated to treatment with cefprozil (30 mg/kg/day divided into two equal doses), an investigational cephalosporin or amoxicillin Clavulanate Potassium (40 mg/kg/day divided into three equal doses) for 10 days. The most common pathogens obtained from middle ear cavities by tympanocentesis were Streptococcus pneumoniae (33%), Haemophilus influenzae (19.6%) and Moraxella catarrhalis (8.3%). Patients were scheduled for follow-up visits at midtreatment, at end of therapy and at 30 days. Of the 137 children 122 were evaluable. Five of 60 patients (8.3%) treated with cefprozil and 14 of 62 patients (22.5%) treated with amoxicillin Clavulanate Potassium were considered therapeutic failures because of persistence of symptoms and/or isolation of the original pathogen or superinfection (P = 0.05). Rates of relapse, reinfection and persistent middle ear effusion as documented by tympanogram were comparable in both groups. When persistent middle ear effusion was analyzed by pneumatic otoscopy, 64 of 103 affected ears (62.1%) treated with cefprozil and 80 of 105 affected ears (76.1%) treated with amoxicillin Clavulanate Potassium were abnormal (P = 0.04). Loose stools were more common in children treated with amoxicillin Clavulanate Potassium than in children treated with cefprozil (P = 0.0004). Based on the efficacy results from this study, the lower gastrointestinal side effects and the convenience of twice-a-day dosing, we believe that cefprozil in a dosage of 30 mg/kg/day divided every 12 hours represents a potential alternative for the treatment of acute otitis media with effusion in children.
Lauren B Charous - One of the best experts on this subject based on the ideXlab platform.
-
effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis
Annals of Allergy Asthma & Immunology, 2002Co-Authors: Anjuli Nayak, Guy A Settipane, Andrew Pedinoff, Lauren B Charous, Eli O Meltzer, William W Busse, James S Zinreich, Richard R Lorber, Ger Rikken, Melvyn R DanzigAbstract:Background Mometasone furoate nasal spray (MFNS) 400 μg, twice daily, as adjunctive treatment with oral antibiotic significantly improved symptoms of recurrent rhinosinusitis. Objective To evaluate the effectiveness and safety of MFNS 200 μg, twice daily, and 400 μg, twice daily, compared with placebo as adjunctive treatment with oral antibiotic for acute rhinosinusitis. Methods In this multicenter, double-blind, placebo-controlled study, 967 outpatients with computed tomographic scan-confirmed moderate to severe rhinosinusitis received amoxicillin/Clavulanate Potassium (Augmentin, GlaxoSmithKline, Research Triangle Park, NC) 875 mg, twice daily, for 21 days with adjunctive twice daily MFNS 200 μg, MFNS 400 μg, or placebo nasal spray. Patients recorded scores of six rhinosinusitis symptoms and any adverse events twice daily. Pre- and postcosyntropin–stimulation plasma cortisol levels were measured in a subset of patients at selected study sites. Results Treatment with MFNS 200 μg or 400 μg, twice daily, produced significantly greater improvements in total symptoms score (primary efficacy variable) day 1 to day 15 average (50% and 51%, respectively) than placebo (44%, P ≤0.017). Both doses of MFNS produced significant total symptoms score improvement over placebo by day 4, and maintained efficacy over the entire 21-day study. Relief of individual symptoms showed a similar pattern. Both doses of MFNS were well tolerated, and adverse events were similar to that of placebo. Cosyntropin stimulation showed no evidence of hypothalamic-pituitary-adrenal axis suppression. Conclusions As adjunctive therapy to oral antibiotic treatment, MFNS at doses of 200 μg or 400 μg, twice daily, was well tolerated and significantly more effective in reducing the symptoms of rhinosinusitis than antibiotic therapy alone.
-
added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Eli O Meltzer, Lauren B Charous, William W Busse, James S Zinreich, Richard R Lorber, Melvyn R DanzigAbstract:Abstract Background: Intranasal glucocorticoids are effective in the treatment of allergic rhinitis. Their effectiveness as an anti-inflammatory adjunct in the treatment of acute recurrent sinusitis has not been adequately established in a controlled clinical study. Objective: The purpose of this study was to test the hypothesis that intranasal corticosteroid treatment produces additional relief in the treatment of acute sinusitis with oral antibiotics. Methods: Patients who were 12 years old and older with a history of recurrent sinusitis were treated while experiencing a new episode of acute sinusitis, which was diagnosed by symptoms and confirmed by computed tomography scan of the paranasal sinuses. Patients were treated for 21 days with amoxicillin Clavulanate Potassium and randomized to receive concurrent mometasone furoate nasal spray (MFNS; Nasonex [400 μg, twice daily]; n=200 patients) or placebo spray (twice daily; n=207 patients). Symptom scores for headache, facial pain, congestion, purulent rhinorrhea, postnasal drip, and cough were recorded at baseline and throughout treatment. Results: Baseline symptom scores showed a moderate level of symptom severity comparable in both groups. Patient-recorded twice daily symptom scores showed that adjunctive treatment with MFNS caused a significantly greater decrease in total symptom score (primary efficacy variable) and in individual scores of inflammatory symptoms associated with the obstruction process (headache, congestion, and facial pain) compared with placebo. Symptoms associated with the secretory processes were improved to a lesser degree. Therapy-related local adverse events were not significantly different between groups. Conclusion: The addition of intranasal corticosteroid, MFNS 400 μg twice daily, to antibiotics significantly reduces symptoms of acute sinusitis compared with antibiotic treatment alone. (J Allergy Clin Immunol 2000;106:630-7.)